Comparison of the clinical efficacy and adverse reaction between everolimus and axitinib in metastatic renal cell carcinoma (mRCC) patients as the second-line treatment

doi:10.3969/j.issn.1672-8467.2020.01.007

LAI Peng, HU Xiao-yi, GUO Jian-ming

Fudan University Journal of Medical Sciences ›› 2020, Vol. 47 ›› Issue (01) : 37-41.

PDF(662 KB)

Fudan University Journal of Medical Sciences ›› 2020, Vol. 47 ›› Issue (01) : 37-41. DOI: 10.3969/j.issn.1672-8467.2020.01.007

The Frontiers of Urology

Comparison of the clinical efficacy and adverse reaction between everolimus and axitinib in metastatic renal cell carcinoma (mRCC) patients as the second-line treatment

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

Abstract

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2020, 47(01): 37-41 https://doi.org/10.3969/j.issn.1672-8467.2020.01.007

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

Funding

RIGHTS & PERMISSIONS

PDF(662 KB)

Accesses

Citation

Detail

Sections

Recommended

Received	Published
2019-08-07	2020-01-25
Issue Date
2020-01-25

Please choose a citation manager

Content to export